These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer's disease-related inhibitory circuit dysfunction in adults with Down syndrome. Belbin O; Xiao MF; Xu D; Carmona-Iragui M; Pegueroles J; Benejam B; Videla L; Fernández S; Barroeta I; Nuñez-Llaves R; Montal V; Vilaplana E; Altuna M; Clarimón J; Alcolea D; Blesa R; Lleó A; Worley PF; Fortea J Mol Neurodegener; 2020 Aug; 15(1):46. PubMed ID: 32807227 [TBL] [Abstract][Full Text] [Related]
4. Amyloid age and tau PET timeline to symptomatic Alzheimer's disease in Down syndrome. Schworer EK; Zammit MD; Wang J; Handen BL; Betthauser T; Laymon CM; Tudorascu DL; Cohen AD; Zaman SH; Ances BM; Mapstone M; Head E; Klunk WE; Christian BT; Hartley SL; medRxiv; 2024 Aug; ():. PubMed ID: 39211859 [TBL] [Abstract][Full Text] [Related]
5. AT(N) biomarker profiles and Alzheimer's disease symptomology in Down syndrome. Hartley SL; Handen B; Tudorascu D; Lee L; Cohen A; Schworer EK; Peven JC; Zammit M; Klunk W; Laymon C; Minhas D; Luo W; Zaman S; Ances B; Preboske G; Christian BT; Alzheimers Dement; 2024 Jan; 20(1):366-375. PubMed ID: 37641428 [TBL] [Abstract][Full Text] [Related]
6. Characterizing the emergence of amyloid and tau burden in Down syndrome. Zammit MD; Betthauser TJ; McVea AK; Laymon CM; Tudorascu DL; Johnson SC; Hartley SL; Converse AK; Minhas DS; Zaman SH; Ances BM; Stone CK; Mathis CA; Cohen AD; Klunk WE; Handen BL; Christian BT; Alzheimers Dement; 2024 Jan; 20(1):388-398. PubMed ID: 37641577 [TBL] [Abstract][Full Text] [Related]
7. Alzheimer's polygenic risk scores are associated with cognitive phenotypes in Down syndrome. Gorijala P; Aslam MM; Dang LT; Xicota L; Fernandez MV; Sung YJ; Fan KH; Feingold E; Surace EI; Chhatwal JP; Hom CL; ; ; Hartley SL; Hassenstab J; Perrin RJ; Mapstone M; Zaman SH; Ances BM; Kamboh MI; Lee JH; Cruchaga C Alzheimers Dement; 2024 Feb; 20(2):1038-1049. PubMed ID: 37855447 [TBL] [Abstract][Full Text] [Related]
11. Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. Fortea J; Vilaplana E; Carmona-Iragui M; Benejam B; Videla L; Barroeta I; Fernández S; Altuna M; Pegueroles J; Montal V; Valldeneu S; Giménez S; González-Ortiz S; Muñoz L; Estellés T; Illán-Gala I; Belbin O; Camacho V; Wilson LR; Annus T; Osorio RS; Videla S; Lehmann S; Holland AJ; Alcolea D; Clarimón J; Zaman SH; Blesa R; Lleó A Lancet; 2020 Jun; 395(10242):1988-1997. PubMed ID: 32593336 [TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid biomarkers of Alzheimer's disease in a cohort of adults with Down syndrome. Henson RL; Doran E; Christian BT; Handen BL; Klunk WE; Lai F; Lee JH; Rosas HD; Schupf N; Zaman SH; Lott IT; Fagan AM Alzheimers Dement (Amst); 2020; 12(1):e12057. PubMed ID: 32671183 [TBL] [Abstract][Full Text] [Related]
13. Neuroimaging and other modalities to assess Alzheimer's disease in Down syndrome. Neale N; Padilla C; Fonseca LM; Holland T; Zaman S Neuroimage Clin; 2018; 17():263-271. PubMed ID: 29159043 [TBL] [Abstract][Full Text] [Related]
14. Integrating Biomarker Outcomes into Clinical Trials for Alzheimer's Disease in Down Syndrome. Rafii MS; Zaman S; Handen BL J Prev Alzheimers Dis; 2021; 8(1):48-51. PubMed ID: 33336224 [TBL] [Abstract][Full Text] [Related]
15. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative. Veitch DP; Weiner MW; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ; Alzheimers Dement; 2019 Jan; 15(1):106-152. PubMed ID: 30321505 [TBL] [Abstract][Full Text] [Related]